Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson’s disease

Intravenous immunoglobulin (IVIg) is a blood-derived product, used for the treatment of immunodeficiency and autoimmune diseases. Since a range of immunotherapies have recently been proposed as a therapeutic strategy for Parkinson’s disease (PD), we investigated the effects of an IVIg treatment in a neurotoxin-induced animal model of PD. Mice received four injections of MPTP (15 mg/kg) at 2-hour intervals followed by a 14-day IVIg treatment, which induced key immune-related changes such as increased regulatory T-cell population and decreased CD4+/CD8+ ratio. The MPTP treatment induced significant 80% and 84% decreases of striatal dopamine concentrations (P < 0.01), as well as 33% and 40% reductions in the number of nigral dopaminergic neurons (P < 0.001) in controls and IVIg-treated mice, respectively. Two-way analyses of variance further revealed lower striatal tyrosine hydroxylase protein levels, striatal homovanillic acid concentrations and nigral dopaminergic neurons (P < 0.05) in IVIg-treated animals. Collectively, our results fail to support a neurorestorative effect of IVIg on the nigrostriatal system in the MPTP-treated mice and even suggest a trend toward a detrimental effect of IVIg on the dopaminergic system. These preclinical data underscore the need to proceed with caution before initiating clinical trials of IVIg in PD patients.

• Publication year

  2012

• Venue

  Journal of Neuroinflammation

• Publication date

  2012-10-09

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1186/1742-2094-9-234PMID 23046563PMCID 3520736
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Corrigendum to ‘Role of natural antibodies in immune homeostasis: IVIg perspective’ [Autoimmun. Rev. 7 (2008) 440–444]

  2013cited by this paper
• Differential modulations of striatal tyrosine hydroxylase and dopamine metabolism by cannabinoid agonists as evidence for functional selectivity in vivo.

  2012cited by this paper
• Partial dopamine depletion in MPTP-treated mice differentially altered motor skill learning and action control.

  2012cited by this paper
• Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson’s disease

  2012cited by this paper
• Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer’s disease

  2012cited by this paper
• High-dose Intravenous Immunoglobulin Treatment Increases Regulatory T Cells in Patients with Eosinophilic Granulomatosis with Polyangiitis

  2012cited by this paper
• High-fat diet exacerbates MPTP-induced dopaminergic degeneration in mice.

  2012cited by this paper
• Classic and New Animal Models of Parkinson's Disease

  2012cited by this paper
• The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration

  2011cited by this paper
• Autoantibody secreting cells and long-lived plasma cells are enriched within inflamed kidneys of NZB/NZW F1 lupus mice and sensitive to bortezomib treatment

  2011cited by this paper
• Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy

  2011cited by this paper
• Murine Motor and Behavior Functional Evaluations for Acute 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Intoxication

  2011cited by this paper
• High frequency of autoantibody‐secreting cells and long‐lived plasma cells within inflamed kidneys of NZB/W F1 lupus mice

  2011cited by this paper
• O4‐06‐02: Effects of human intravenous immunoglobulins on amyloid pathology and inflammation in a mouse model of Alzheimer's disease

  2011cited by this paper
• Intravenous immunoglobulin G (IVIG) inhibits IL-1- and TNF-α-dependent, but not chemotactic-factor-stimulated, neutrophil transendothelial migration.

  2011cited by this paper
• Pathological roles of α-synuclein in neurological disorders.

  2011cited by this paper
• Press Review

  2011cited by this paper
• Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis.

  2011cited by this paper
• Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine)-induced mouse model of Parkinson's disease.

  2011cited by this paper
• α-Synuclein Reactive Antibodies as Diagnostic Biomarkers in Blood Sera of Parkinson's Disease Patients

  2011cited by this paper
• Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease

  2011cited by this paper
• Tyrosine hydroxylase and regulation of dopamine synthesis.

  2011cited by this paper
• Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies.

  2011cited by this paper
• Progesterone receptor isoforms differentially regulate the expression of tryptophan and tyrosine hydroxylase and glutamic acid decarboxylase in the rat hypothalamus.

  2011cited by this paper
• Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease

  2011cited by this paper
• Modulation of Tyrosine Hydroxylase, Neuropeptide Y, Glutamate, and Substance P in Ganglia and Brain Areas Involved in Cardiovascular Control after Chronic Exposure to Nicotine

  2011cited by this paper
• Blocking IL-1 Signaling Rescues Cognition, Attenuates Tau Pathology, and Restores Neuronal β-Catenin Pathway Function in an Alzheimer’s Disease Model

  2011cited by this paper
• A tale on animal models of Parkinson's disease

  2011cited by this paper
• Parkinson's disease is associated with increased serum levels of macrophage migration inhibitory factor.

  2011cited by this paper
• Novel role of aquaporin‐4 in CD4+ CD25+ T regulatory cell development and severity of Parkinson’s disease

  2011cited by this paper
• Passively Administered Pooled Human Immunoglobulins Exert IL-10 Dependent Anti-Inflammatory Effects that Protect against Fatal HSV Encephalitis

  2011cited by this paper
• Defective FOXP3 expression in patients with acute Kawasaki disease and restoration by intravenous immunoglobulin therapy.

  2010cited by this paper
• Missing pieces in the Parkinson's disease puzzle

  2010cited by this paper
• Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease

  2010cited by this paper
• In vivo modulation of the expressions of Fas and CD25 by intravenous immunoglobulin in common variable immunodeficiency

  2010cited by this paper
• Regulatory T Cells Attenuate Th17 Cell-Mediated Nigrostriatal Dopaminergic Neurodegeneration in a Model of Parkinson’s Disease

  2010cited by this paper
• FOXP3+ regulatory T cells in the human immune system

  2010cited by this paper
• Control of Th2-mediated inflammation by regulatory T cells.

  2010cited by this paper
• The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson’s disease

  2010cited by this paper
• Involvement of Fc Receptors in Disorders of the Central Nervous System

  2010cited by this paper
• Mechanisms of IVIG Efficacy in Chronic Inflammatory Demyelinating Polyneuropathy

  2010cited by this paper
• MPTP-Induced Neuroinflammation Increases the Expression of Pro-Inflammatory Cytokines and Their Receptors in Mouse Brain

  2010cited by this paper
• Sugar-free, glycine-stabilized intravenous immunoglobulin prevents skin but not renal disease in the MRL/lpr mouse model of systemic lupus

  2010cited by this paper
• Improved mouse models for the study of treatment modalities for immune‐mediated platelet destruction

  2010cited by this paper
• Intravenous Immunoglobulins as a Treatment for Alzheimer’s Disease

  2010cited by this paper
• Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance.

  2010cited by this paper
• Specific antibodies to soluble alpha‐synuclein conformations in intravenous immunoglobulin preparations

  2010cited by this paper
• A2A adenosine receptor overexpression and functionality, as well as TNF‐α levels, correlate with motor symptoms in Parkinson's disease

  2010cited by this paper
• Apoptosis of peripheral blood lymphocytes in Parkinson patients.

  2010cited by this paper
• Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation.

  2010cited by this paper
• Interleukin-6 Serum Levels in Patients with Parkinson’s Disease

  2009cited by this paper
• 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

  2009cited by this paper
• Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and α‐synuclein inclusions

  2009cited by this paper
• Therapeutic activities of intravenous immunoglobulins in multiple sclerosis involve modulation of chemokine expression.

  2009cited by this paper
• Increased serum levels of soluble tumor necrosis factor-alpha receptor-1 in patients with Parkinson's disease.

  2009cited by this paper
• Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease.

  2008cited by this paper
• Anti-inflammatory actions of intravenous immunoglobulin.

  2008cited by this paper
• Safety and Efficacy of Privigen®, a Novel 10% Liquid Immunoglobulin Preparation for Intravenous Use, in Patients with Primary Immunodeficiencies

  2008cited by this paper
• Variation of anti‐Fas antibodies in different lots of intravenous immunoglobulin

  2008cited by this paper
• Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis.

  2008cited by this paper
• Beneficial effects of dietary omega‐3 polyunsaturated fatty acid on toxin‐induced neuronal degeneration in an animal model of Parkinson's disease

  2008cited by this paper
• Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy.

  2008influential reference
• Role of natural antibodies in immune homeostasis: IVIg perspective.

  2008cited by this paper
• Intravenous Immunoglobulin: An Update on the Clinical Use and Mechanisms of Action

  2007cited by this paper
• Biochemical Characterization of Aβ and Tau Pathologies in Mild Cognitive Impairment and Alzheimer's Disease

  2007cited by this paper
• p53 protein, interferon-γ, and NF-κB levels are elevated in the parkinsonian brain

  2007cited by this paper
• Intravenous Immunoglobulins in Autoimmune and Inflammatory Diseases

  2007cited by this paper
• p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain.

  2007cited by this paper
• Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration.

  2007cited by this paper
• Neuroinflammation in Parkinson's patients and MPTP-treated mice is not restricted to the nigrostriatal system: microgliosis and differential expression of interleukin-1 receptors in the olfactory bulb.

  2007cited by this paper
• Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer's disease.

  2007cited by this paper
• Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease

  2007cited by this paper
• Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease.

  2007cited by this paper
• Protocol for the MPTP mouse model of Parkinson's disease

  2007influential reference
• A call for clinically driven experimental design in assessing neuroprotection in experimental Parkinsonism.

  2006cited by this paper
• Autoantibodies to alpha‐synuclein in inherited Parkinson’s disease

  2006cited by this paper
• Behavioral models of Parkinson's disease in rodents: A new look at an old problem

  2006cited by this paper
• Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms.

  2006cited by this paper
• IVIg attenuates T cell-mediated killing of human neurons.

  2006cited by this paper
• Mice lacking alpha-synuclein are resistant to mitochondrial toxins.

  2006cited by this paper
• CD4+/CD8+ macrophages infiltrating at inflammatory sites: a population of monocytes/macrophages with a cytotoxic phenotype.

  2006cited by this paper
• Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease.

  2005cited by this paper
• Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.

  2005cited by this paper
• A possible role for humoral immunity in the pathogenesis of Parkinson's disease.

  2005cited by this paper
• Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

  2005cited by this paper
• Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease

  2005cited by this paper
• Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials.

  2004cited by this paper
• Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice.

  2004cited by this paper
• Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.

  2004cited by this paper
• Toxic epidermal necrolysis treated with low‐dose intravenous immunoglobulin: immunohistochemical study of Fas and Fas‐Ligand expression

  2004cited by this paper
• IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment.

  2004cited by this paper
• Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of γ‐synuclein, α‐synuclein and double α/γ‐synuclein null mutant mice

  2004cited by this paper
• Tyrosine hydroxylase and dopamine transporter expression following 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced neurodegeneration of the mouse nigrostriatal pathway

  2004cited by this paper
• Clinical pharmacology and neuroprotection in Parkinson's disease.

  2003cited by this paper
• The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease.

  2003cited by this paper
• Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial.

  2003cited by this paper
• Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%).

  2003cited by this paper
• Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.

  2003cited by this paper
• Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice.

  2003cited by this paper
• Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV‐C, 10% (Gamunex™, 10%)

  2003cited by this paper

• Fc-Modified IVIG with Enhanced Blood–Brain Barrier Penetration Ameliorates Cognitive Deficits and Neuropathology in A53T α-Synuclein Transgenic Mice

  2025cites this paper
• Cinnamaldehyde Attenuates the Expression of IBA1 and GFAP to Inhibit Glial Cell Activation and Inflammation in the MPTP-Induced Acute Parkinson's Disease Model

  2024cites this paper
• Disease mechanisms as subtypes: Immune dysfunction in Parkinson's disease.

  2023cites this paper
• Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice

  2022cites this paper
• A Comparison Between 1 Day versus 7 Days of Sepsis in Mice with the Experiments on LPS-Activated Macrophages Support the Use of Intravenous Immunoglobulin for Sepsis Attenuation

  2021cites this paper
• Naturally occurring autoantibodies against α-synuclein rescues memory and motor deficits and attenuates α-synuclein pathology in mouse model of Parkinson's disease.

  2019cites this paper
• Peripheral adaptive immunity of the triple transgenic mouse model of Alzheimer’s disease

  2019cites this paper
• Phytic acid attenuates upregulation of GSK-3β and disturbance of synaptic vesicle recycling in MPTP-induced Parkinson's disease models.

  2019cites this paper
• IVIG Delays Onset in a Mouse Model of Gerstmann-Sträussler-Scheinker Disease

  2018cites this paper
• Effets de l’administration de tétrahydrobioptérine en condition physiologique et pathologique : De la neurobiologie au comportement

  2018cites this paper
• IVIG activates FcγRIIB-SHIP1-PIP3 Pathway to stabilize mast cells and suppress inflammation after ICH in mice

  2017cites this paper
• Prokineticin-2 upregulation during neuronal injury mediates a compensatory protective response against dopaminergic neuronal degeneration

  2016cites this paper
• EFFECT OF FVIII CO-ADMINISTRATED WITH IVIG IN IMMUNITY TO FVIII IN HEMOPHILIA A MICE

  2016influential citation
• Differences in Anti-Inflammatory Actions of Intravenous Immunoglobulin between Mice and Men: More than Meets the Eye

  2015cites this paper
• Immunomodulatory Mechanisms of Intravenous Immunoglobulin

  2014cites this paper
• Intravenous immunoglobulins for Alzheimer's disease.

  2014cites this paper
• Vaccination strategies for Parkinson disease

  2014influential citation
• IVIg protects the 3xTg-AD mouse model of Alzheimer’s disease from memory deficit and Aβ pathology

  2014cites this paper
• Brain Bioavailability of Human Intravenous Immunoglobulin and its Transport through the Murine Blood–Brain Barrier

  2013cites this paper